A recent trial NCT02007512 using the AI exemestane, with or without enzalutamide, in patients with ER+ advanced/metastatic disease found that high levels of AR and low levels of ESR1 were associated with the significantly greater benefit of enzalutamide20. Here, AR is linked to metastatic neoplasm.